Skip to main content

Multiple Myeloma

Daratumumab plus Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Long-Term Outcomes from MAIA

Patient and Caregiver Preferences for RRMM Treatment Should Be Considered Using Shared Decision-Making

Ciltacabtagene Autoleucel Shows Promising Results in Patients with Multiple Myeloma Who Have Experienced Early Clinical Relapse

Updated Results from IKEMA Demonstrate a Median PFS of Nearly 3 Years with Isa-Kd

Daratumumab + Cyclophosphamide, Bortezomib, and Dexamethasone Induction Followed by Daratumumab Maintenance Achieved Durable Responses in Patients with RRMM and NDMM

Addition of ASCT to Triplet Induction and Lenalidomide Maintenance to Progression: Results from the DETERMINATION Trial

Carvykti Second BCMA-Directed CAR T-Cell Therapy FDA Approved for Multiple Myeloma

Phase 1/2 Study Results of BCMA x CD3 Bispecific Monoclonal Antibody REGN5458 in Patients with RRMM

Phase 1b TRIMM-2 Trial Results for Subcutaneous Talquetamab plus Daratumumab in Patients with RRMM

Subgroup Analysis of the FORTE Study by Risk Categories of Carfilzomib-Based Induction/Consolidation with or without Autologous Transplant and Lenalidomide or Carfilzomib-Lenalidomide Maintenance

1
2
3
4
5
6

Page 3 of 11
Results 21 - 30 of 104